Vir Biotechnology misses Q3 revenue estimates

Reuters

Nov 06

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> misses Q3 revenue estimates

Overview

Vir Biotechnology Q3 revenue missed analyst expectations, declining significantly year-over-year
Net loss for Q3 decreased to $163.1 mln from $213.7 mln year-over-year
Company maintains strong cash position with $810.7 mln, funding operations into mid-2027

Outlook

Company expects cash reserves to fund operations into mid-2027
Topline data for ECLIPSE trials expected in Q1 2027

Result Drivers

R&D expenses for the third quarter of 2025 were $151.5 million, compared to $195.2 million for the same period in 2024
ONCOLOGY EXPANSION - First patient dosed in Phase 1 study of VIR-5500 in combination with ARPIs for prostate cancer

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$200,000	$1.98 mln (7 Analysts)
Q3 EPS		-$1.17
Q3 Net Income		-$163.10 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vir Biotechnology Inc is $15.00, about 65% above its November 4 closing price of $5.25

Press Release: ID:nBwYcK9Qa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2581702436"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581702436\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581702436?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581702436","market":"nz","top_or_hot":-1,"title":"Vir Biotechnology misses Q3 revenue estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> misses Q3 revenue estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Vir Biotechnology Q3 revenue missed analyst expectations, declining significantly year-over-year</p></li><li><p>Net loss for Q3 decreased to $163.1 mln from $213.7 mln year-over-year</p></li><li><p>Company maintains strong cash position with $810.7 mln, funding operations into mid-2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash reserves to fund operations into mid-2027</p></li><li><p>Topline data for ECLIPSE trials expected in Q1 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D expenses for the third quarter of 2025 were $151.5 million, compared to $195.2 million for the same period in 2024</p></li><li><p>ONCOLOGY EXPANSION - First patient dosed in Phase 1 study of VIR-5500 in combination with ARPIs for prostate cancer</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$200,000</p></td><td><p>$1.98 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$1.17</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$163.10 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vir Biotechnology Inc is $15.00, about 65% above its November 4 closing price of $5.25</p></li></ul><p>Press Release: <span>ID:nBwYcK9Qa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology misses Q3 revenue estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology misses Q3 revenue estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> misses Q3 revenue estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Vir Biotechnology Q3 revenue missed analyst expectations, declining significantly year-over-year</p></li><li><p>Net loss for Q3 decreased to $163.1 mln from $213.7 mln year-over-year</p></li><li><p>Company maintains strong cash position with $810.7 mln, funding operations into mid-2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash reserves to fund operations into mid-2027</p></li><li><p>Topline data for ECLIPSE trials expected in Q1 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D expenses for the third quarter of 2025 were $151.5 million, compared to $195.2 million for the same period in 2024</p></li><li><p>ONCOLOGY EXPANSION - First patient dosed in Phase 1 study of VIR-5500 in combination with ARPIs for prostate cancer</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$200,000</p></td><td><p>$1.98 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$1.17</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$163.10 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vir Biotechnology Inc is $15.00, about 65% above its November 4 closing price of $5.25</p></li></ul><p>Press Release: <span>ID:nBwYcK9Qa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH1GK:1","article_id":"2581702436","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581702436","pubTimestamp":1762377848,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology misses Q3 revenue estimatesOverviewVir Biotechnology Q3 revenue missed analyst expectations, declining significantly year-over-yearNet loss for Q3 decreased to $163.1 mln from $213.7","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4535":"淡马锡持仓","VIR":"Vir Biotechnology, Inc.","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"Vir Biotechnology未达到第三季度收入预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology misses Q3 revenue estimatesOverviewVir Biotechnology Q3 revenue missed analyst expectations, declining significantly year-over-yearNet loss for Q3 decreased to $163.1 mln from $213.7 mln year-over-yearCompany maintains strong cash position with $810.7 mln, funding operations into mid-2027OutlookCompany expects cash reserves to fund operations into mid-2027Topline data for ECLIPSE trials expected in Q1 2027Result DriversR&D expenses for the third quarter of 2025 were $151.5 million, compared to $195.2 million for the same period in 2024ONCOLOGY EXPANSION - First patient dosed in Phase 1 study of VIR-5500 in combination with ARPIs for prostate cancerKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$200,000$1.98 mln (7 Analysts)Q3 EPS-$1.17Q3 Net Income-$163.10 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Vir Biotechnology Inc is $15.00, about 65% above its November 4 closing price of $5.25Press Release: ID:nBwYcK9QaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}